select a format

Single User License
USD 2000 INR 129580
Site License
USD 4000 INR 259160
Corporate User License
USD 6000 INR 388740

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Diabetic Retinopathy-Pipeline Review, H2 2015

Diabetic Retinopathy-Pipeline Review, H2 2015


  • Products Id :- GMDHC7216IDB
  • |
  • Pages: 208
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Diabetic Retinopathy-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Diabetic Retinopathy-Pipeline Review, H2 2015', provides an overview of the Diabetic Retinopathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Diabetic Retinopathy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Diabetic Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Diabetic Retinopathy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Diabetic Retinopathy Overview 9

Therapeutics Development 10

Pipeline Products for Diabetic Retinopathy-Overview 10

Pipeline Products for Diabetic Retinopathy-Comparative Analysis 11

Diabetic Retinopathy-Therapeutics under Development by Companies 12

Diabetic Retinopathy-Therapeutics under Investigation by Universities/Institutes 17

Diabetic Retinopathy-Pipeline Products Glance 18

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Diabetic Retinopathy-Products under Development by Companies 21

Diabetic Retinopathy-Products under Investigation by Universities/Institutes 25

Diabetic Retinopathy-Companies Involved in Therapeutics Development 26

Acucela Inc. 26

Aerpio Therapeutics, Inc. 27

Angstrom Pharmaceuticals, Inc. 28

Antisense Therapeutics Limited 29

BCN Peptides, S.A. 30

BioDiem Ltd 31

Biomar Microbial Technologies 32

Charlesson LLC. 33

Crinetics Pharmaceuticals, Inc. 34

Dimerix Bioscience Pty Ltd 35

Dynamis Therapeutics, Inc. 36

EyeGene, Inc. 37

Foresee Pharmaceuticals, LLC 38

GTx, Inc. 39

Icon Bioscience, Inc. 40

IMMD Inc. 41

Islet Sciences, Inc. 42

Kowa Company, Ltd. 43

LegoChem Biosciences, Inc 44

Lpath, Inc. 45

Mabion SA 46

MacuCLEAR, Inc. 47

MingSight Pharmaceuticals 48

OcuCure Therapeutics, Inc. 49

Oculis ehf 50

Ohr Pharmaceutical Inc. 51

PanOptica, Inc. 52

Promedior, Inc. 53

R-Tech Ueno, Ltd. 54

RestorGenex Corporation 55

Ribomic Inc. 56

Sirnaomics, Inc. 57

Stelic Institute & Co. 58

Stemedica Cell Technologies, Inc. 59

Strongbridge Biopharma plc 60

Targazyme, Inc. 61

ThromboGenics NV 62

TWi Pharmaceuticals, Inc. 63

VasGene Therapeutics, Inc. 64

Xbrane Bioscience AB 65

Diabetic Retinopathy-Therapeutics Assessment 66

Assessment by Monotherapy Products 66

Assessment by Target 67

Assessment by Mechanism of Action 70

Assessment by Route of Administration 73

Assessment by Molecule Type 75

Drug Profiles 77

A-6-Drug Profile 77

A-717-Drug Profile 79

AC-301-Drug Profile 80

AKB-9778-Drug Profile 81

ALG-1001-Drug Profile 83

ATL-1103-Drug Profile 85

BCN-070660-Drug Profile 87

BDM-E-Drug Profile 88

Beta-LGND2-Drug Profile 90

CLT-01001-Drug Profile 92

CLT-01007-Drug Profile 93

CLT-01012-Drug Profile 94

COR-005-Drug Profile 95

cyclosporine-Drug Profile 98

Cyndacel-M-Drug Profile 99

DMX-200-Drug Profile 101

DMX-400-Drug Profile 102

Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy-Drug Profile 103

DT-23552-Drug Profile 104

DYN-12-Drug Profile 105

E-1086-Drug Profile 107

EG-Mirotin-Drug Profile 108

emixustat hydrochloride-Drug Profile 110

FP-008-Drug Profile 112

Granzyme B/VEGF-Drug Profile 113

IB-09A0133-Drug Profile 114

IMD-0354-Drug Profile 115

JP-153-Drug Profile 116

L-779976-Drug Profile 117

LCB-030110-Drug Profile 118

Lycium Anti-Angiogenic Proteoglycan-Drug Profile 119

MC-4001-Drug Profile 120

Mesenchymal Stem Cells-Drug Profile 121

Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy-Drug Profile 123

MS-553-Drug Profile 124

Nextomabs-Drug Profile 125

NM-108-Drug Profile 126

OC-10X-Drug Profile 127

OC-410-Drug Profile 128

ocriplasmin (recombinant)-Drug Profile 129

OCU-200-Drug Profile 132

OLX-302-Drug Profile 133

PAN-90806-Drug Profile 134

PRM-167-Drug Profile 136

Protein for Oncology, Ophthalmology and Metabolic Disorders-Drug Profile 137

ranibizumab biosimilar-Drug Profile 138

ranibizumab biosimilar-Drug Profile 139

RBM-008-Drug Profile 140

Recombinant Protein for Cancer and Diabetic Retinopathy-Drug Profile 141

RES-529-Drug Profile 142

ripasudil-Drug Profile 144

RTU-007-Drug Profile 145

RTU-1096-Drug Profile 146

squalamine lactate-Drug Profile 147

Stem Cell Therapy for Diabetic Retinopathy-Drug Profile 150

STNM-1510-Drug Profile 151

STP-601-Drug Profile 152

TZ-101-Drug Profile 153

V-1932-Drug Profile 155

Vas-02-Drug Profile 156

Diabetic Retinopathy-Recent Pipeline Updates 157

Diabetic Retinopathy-Dormant Projects 188

Diabetic Retinopathy-Discontinued Products 193

Diabetic Retinopathy-Product Development Milestones 194

Featured News & Press Releases 194

Appendix 203

Methodology 203

Coverage 203

Secondary Research 203

Primary Research 203

Expert Panel Validation 203

Contact Us 203

Disclaimer 204

List of Tables

Number of Products under Development for Diabetic Retinopathy, H2 2015 14

Number of Products under Development for Diabetic Retinopathy-Comparative Analysis, H2 2015 15

Number of Products under Development by Companies, H2 2015 17

Number of Products under Development by Companies, H2 2015 (Contd..1) 18

Number of Products under Development by Companies, H2 2015 (Contd..2) 19

Number of Products under Development by Companies, H2 2015 (Contd..3) 20

Number of Products under Investigation by Universities/Institutes, H2 2015 21

Comparative Analysis by Clinical Stage Development, H2 2015 22

Comparative Analysis by Early Stage Development, H2 2015 23

Comparative Analysis by Unknown Stage Development, H2 2015 24

Products under Development by Companies, H2 2015 25

Products under Development by Companies, H2 2015 (Contd..1) 26

Products under Development by Companies, H2 2015 (Contd..2) 27

Products under Development by Companies, H2 2015 (Contd..3) 28

Products under Investigation by Universities/Institutes, H2 2015 29

Diabetic Retinopathy-Pipeline by Acucela Inc., H2 2015 30

Diabetic Retinopathy-Pipeline by Aerpio Therapeutics, Inc., H2 2015 31

Diabetic Retinopathy-Pipeline by Angstrom Pharmaceuticals, Inc., H2 2015 32

Diabetic Retinopathy-Pipeline by Antisense Therapeutics Limited, H2 2015 33

Diabetic Retinopathy-Pipeline by BCN Peptides, S.A., H2 2015 34

Diabetic Retinopathy-Pipeline by BioDiem Ltd, H2 2015 35

Diabetic Retinopathy-Pipeline by Biomar Microbial Technologies, H2 2015 36

Diabetic Retinopathy-Pipeline by Charlesson LLC., H2 2015 37

Diabetic Retinopathy-Pipeline by Crinetics Pharmaceuticals, Inc., H2 2015 38

Diabetic Retinopathy-Pipeline by Dimerix Bioscience Pty Ltd, H2 2015 39

Diabetic Retinopathy-Pipeline by Dynamis Therapeutics, Inc., H2 2015 40

Diabetic Retinopathy-Pipeline by EyeGene, Inc., H2 2015 41

Diabetic Retinopathy-Pipeline by Foresee Pharmaceuticals, LLC, H2 2015 42

Diabetic Retinopathy-Pipeline by GTx, Inc., H2 2015 43

Diabetic Retinopathy-Pipeline by Icon Bioscience, Inc., H2 2015 44

Diabetic Retinopathy-Pipeline by IMMD Inc., H2 2015 45

Diabetic Retinopathy-Pipeline by Islet Sciences, Inc., H2 2015 46

Diabetic Retinopathy-Pipeline by Kowa Company, Ltd., H2 2015 47

Diabetic Retinopathy-Pipeline by LegoChem Biosciences, Inc, H2 2015 48

Diabetic Retinopathy-Pipeline by Lpath, Inc., H2 2015 49

Diabetic Retinopathy-Pipeline by Mabion SA, H2 2015 50

Diabetic Retinopathy-Pipeline by MacuCLEAR, Inc., H2 2015 51

Diabetic Retinopathy-Pipeline by MingSight Pharmaceuticals, H2 2015 52

Diabetic Retinopathy-Pipeline by OcuCure Therapeutics, Inc., H2 2015 53

Diabetic Retinopathy-Pipeline by Oculis ehf, H2 2015 54

Diabetic Retinopathy-Pipeline by Ohr Pharmaceutical Inc., H2 2015 55

Diabetic Retinopathy-Pipeline by PanOptica, Inc., H2 2015 56

Diabetic Retinopathy-Pipeline by Promedior, Inc., H2 2015 57

Diabetic Retinopathy-Pipeline by R-Tech Ueno, Ltd., H2 2015 58

Diabetic Retinopathy-Pipeline by RestorGenex Corporation, H2 2015 59

Diabetic Retinopathy-Pipeline by Ribomic Inc., H2 2015 60

Diabetic Retinopathy-Pipeline by Sirnaomics, Inc., H2 2015 61

Diabetic Retinopathy-Pipeline by Stelic Institute & Co., H2 2015 62

Diabetic Retinopathy-Pipeline by Stemedica Cell Technologies, Inc., H2 2015 63

Diabetic Retinopathy-Pipeline by Strongbridge Biopharma plc , H2 2015 64

Diabetic Retinopathy-Pipeline by Targazyme, Inc., H2 2015 65

Diabetic Retinopathy-Pipeline by ThromboGenics NV, H2 2015 66

Diabetic Retinopathy-Pipeline by TWi Pharmaceuticals, Inc., H2 2015 67

Diabetic Retinopathy-Pipeline by VasGene Therapeutics, Inc., H2 2015 68

Diabetic Retinopathy-Pipeline by Xbrane Bioscience AB, H2 2015 69

Assessment by Monotherapy Products, H2 2015 70

Number of Products by Stage and Target, H2 2015 72

Number of Products by Stage and Mechanism of Action, H2 2015 75

Number of Products by Stage and Route of Administration, H2 2015 78

Number of Products by Stage and Molecule Type, H2 2015 80

Diabetic Retinopathy Therapeutics-Recent Pipeline Updates, H2 2015 161

Diabetic Retinopathy-Dormant Projects, H2 2015 192

Diabetic Retinopathy-Dormant Projects (Contd..1), H2 2015 193

Diabetic Retinopathy-Dormant Projects (Contd..2), H2 2015 194

Diabetic Retinopathy-Dormant Projects (Contd..3), H2 2015 195

Diabetic Retinopathy-Dormant Projects (Contd..4), H2 2015 196

Diabetic Retinopathy-Discontinued Products, H2 2015 197

List of Figures

Number of Products under Development for Diabetic Retinopathy, H2 2015 14

Number of Products under Development for Diabetic Retinopathy-Comparative Analysis, H2 2015 15

Number of Products under Development by Companies, H2 2015 16

Comparative Analysis by Clinical Stage Development, H2 2015 22

Comparative Analysis by Early Stage Products, H2 2015 23

Assessment by Monotherapy Products, H2 2015 70

Number of Products by Top 10 Targets, H2 2015 71

Number of Products by Stage and Top 10 Targets, H2 2015 71

Number of Products by Top 10 Mechanism of Actions, H2 2015 74

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 74

Number of Products by Top 10 Routes of Administration, H2 2015 77

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 77

Number of Products by Top 10 Molecule Types, H2 2015 79

Number of Products by Stage and Top 10 Molecule Types, H2 2015 79

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acucela Inc.

Aerpio Therapeutics, Inc.

Angstrom Pharmaceuticals, Inc.

Antisense Therapeutics Limited

BCN Peptides, S.A.

BioDiem Ltd

Biomar Microbial Technologies

Charlesson LLC.

Crinetics Pharmaceuticals, Inc.

Dimerix Bioscience Pty Ltd

Dynamis Therapeutics, Inc.

EyeGene, Inc.

Foresee Pharmaceuticals, LLC

GTx, Inc.

Icon Bioscience, Inc.

IMMD Inc.

Islet Sciences, Inc.

Kowa Company, Ltd.

LegoChem Biosciences, Inc

Lpath, Inc.

Mabion SA

MacuCLEAR, Inc.

MingSight Pharmaceuticals

OcuCure Therapeutics, Inc.

Oculis ehf

Ohr Pharmaceutical Inc.

PanOptica, Inc.

Promedior, Inc.

R-Tech Ueno, Ltd.

RestorGenex Corporation

Ribomic Inc.

Sirnaomics, Inc.

Stelic Institute & Co.

Stemedica Cell Technologies, Inc.

Strongbridge Biopharma plc

Targazyme, Inc.

ThromboGenics NV

TWi Pharmaceuticals, Inc.

VasGene Therapeutics, Inc.

Xbrane Bioscience AB

Diabetic Retinopathy Therapeutic Products under Development, Key Players in Diabetic Retinopathy Therapeutics, Diabetic Retinopathy Pipeline Overview, Diabetic Retinopathy Pipeline, Diabetic Retinopathy Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com